A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization

Berin, Inna; Stein, Daniel E.; Keltz, Martin D.

doi:10.1016/j.fertnstert.2008.11.007

Cited by 29 publications

(16 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This has clearly been done in clinical cases of tamoxifen, a pharmaceutical estrogen receptor antagonist, which produces NMDRCs: when first administered to women, low concentrations in blood stimulate tumor growth, and then as the internal concentrations increase, high doses inhibit tumor growth [130–133]. It has also been demonstrated in clinical cases of Lupron treatment, a pharmaceutical agonist of gonadotropin releasing hormone, which also produces NMDRCs: at low doses, Lupron stimulates FSH and therefore induces ovulation, whereas high doses suppress the ovarian response [134, 135]. …”

Section: 3 Issue # 3: Debate Surrounding Non-monotonicity In Edc Stmentioning

confidence: 99%

Regulatory decisions on endocrine disrupting chemicals should be based on the principles of endocrinology

Vandenberg

Colborn

Hayes

et al. 2013

Reproductive Toxicology

190

109

View full text Add to dashboard Cite

For years, scientists from various disciplines have studied the effects of endocrine disrupting chemicals (EDCs) on the health and wellbeing of humans and wildlife. Some studies have specifically focused on the effects of low doses, i.e. those in the range that are thought to be safe for humans and/or animals. Others have focused on the existence of non-monotonic dose-response curves. These concepts challenge the way that chemical risk assessment is performed for EDCs. Continued discussions have clarified exactly what controversies and challenges remain. We address several of these issues, including why the study and regulation of EDCs should incorporate endocrine principles; what level of consensus there is for low dose effects; challenges to our understanding of non-monotonicity; and whether EDCs have been demonstrated to produce adverse effects. This discussion should result in a better understanding of these issues, and allow for additional dialogue on their impact on risk assessment.

show abstract

Section: 3 Issue # 3: Debate Surrounding Non-monotonicity In Edc Stmentioning

confidence: 99%

Regulatory decisions on endocrine disrupting chemicals should be based on the principles of endocrinology

Vandenberg

Colborn

Hayes

et al. 2013

Reproductive Toxicology

190

109

View full text Add to dashboard Cite

show abstract

“…A microdose agonist protocol was also proposed by Schoolcraft and associates [80], with both protocols attempting to avoid suppressive effects on ovaries. Others see no difference between microdose agonist and antagonist protocols [81,82]. Appropriately controlled studies are lacking.…”

Section: Introductionmentioning

confidence: 99%

Defining ovarian reserve to better understand ovarian aging

Gleicher

Weghofer

Barad

2011

Reprod Biol Endocrinol

163

130

View full text Add to dashboard Cite

Though a widely utilized term and clinical concept, ovarian reserve (OR) has been only inadequately defined. Based on Medline and PubMed searches we here define OR in its various components, review genetic control of OR, with special emphasis on the FMR1 gene, and discuss whether diminished OR (DOR) is treatable. What is generally referred to as OR reflects only a small portion of total OR (TOR), a pool of growing (recruited) follicles (GFs) at different stages of maturation. Functional OR (FOR) depends on size of the follicle pool at menarche and the follicle recruitment rate. Both vary between individuals and, at least partially, are under genetic control. The FMR1 gene plays a role in defining FOR at all ages. Infertility treatments have in the past almost exclusively only centered on the last two weeks of folliculogenesis, the gonadotropin-sensitive phase. Expansions of treatments into earlier stages of maturation will offer opportunity to significantly improve ovarian stimulation protocols, especially in women with DOR. Dehydroepiandrosterone (DHEA) may represent a first such intervention. Data generated in DHEA-supplemented women, indeed, suggest a new ovarian aging concept, based on aging of ovarian environments and not, as currently is believed, aging oocytes.

show abstract

“…In a study which compared GnRH antagonist protocol with GnRH agonist flare-up protocol in poor responders, Berin at al. [19] found excellent and comparable pregnancy and live birth rates in poor responders of advanced reproductive age with the use of either GnRH antagonist or flare protocol.…”

Section: Discussionmentioning

confidence: 90%

The comparison of microdose flare up and flexible antagonist protocols in poor responders undergoing IVF treatment: A prospective randomized controlled trial

Özdoğan¹,

Özdeğirmenci²,

Dilbaz³

et al. 2018

Journal of Surgery and Medicine

View full text Add to dashboard Cite

show abstract

A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization

Cited by 29 publications

References 19 publications

Regulatory decisions on endocrine disrupting chemicals should be based on the principles of endocrinology

Regulatory decisions on endocrine disrupting chemicals should be based on the principles of endocrinology

Defining ovarian reserve to better understand ovarian aging

The comparison of microdose flare up and flexible antagonist protocols in poor responders undergoing IVF treatment: A prospective randomized controlled trial

Contact Info

Product

Resources

About